Lipid-modified G4-decoy oligonucleotide anchored to nanoparticles: delivery and bioactivity in pancreatic cancer cells

KRAS is mutated in >90% of pancreatic ductal adenocarcinomas. As its inactivation leads to tumour regression, mutant KRAS is considered an attractive target for anticancer drugs. In this study we report a new delivery strategy for a G4-decoy oligonucleotide that sequesters MAZ, a transcription fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cogoi, S., Jakobsen, U., Pedersen, E. B., Vogel, S., Xodo, L. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144097/
https://www.ncbi.nlm.nih.gov/pubmed/27929127
http://dx.doi.org/10.1038/srep38468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144097/
https://www.ncbi.nlm.nih.gov/pubmed/27929127
http://dx.doi.org/10.1038/srep38468

Ejemplares similares